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Abstract
Background: Approximately 418,000 people live in care homes in the UK, yet accessible, robust data on care home
populations and organisation are lacking. This hampers our ability to plan, allocate resources or prevent risk. Large
randomised controlled trials (RCTs) conducted in care homes offer a potential solution. The value of detailed data
on residents’ demographics, outcomes and contextual information captured in RCTs has yet to be fully realised.
Irrespective of the intervention tested, much of the trial data collected overlaps in terms of structured assessments
and descriptive information. Given the time and costs required to prospectively collect data in these populations,
pooling anonymised RCT data into a structured repository offers benefit; secondary analyses of pooled RCT data
can improve understanding of this under-researched population and enhance the future trial design. This protocol
describes the creation of a project-specific repository of individual participant data (IPD) from trials conducted in
care homes and subsequent expansion into a legacy dataset for wider use, to address the need for accurate, high-
quality IPD on this vulnerable population.
Methods: Informed by scoping of relevant literature, the principal investigators of RCTs conducted in adult care
homes in the UK since 2010 will be invited to contribute trial IPD. Contributing trialists will form a Steering
Committee who will oversee data sharing and remain gatekeepers of their own trial’s data. IPD will be cleaned and
standardised in consultation with the Steering Committee for accuracy. Planned analyses include a comparison of
pooled IPD with point estimates from administrative sources, to assess generalisability of RCT data to the wider care
home population. We will also identify key resident characteristics and outcomes from within the trial repository,
which will inform the development of a national minimum dataset for care homes. Following project completion,
management will migrate to the Virtual Trials Archives, forming a legacy dataset which will be expanded to include
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international RCTs, and will be accessible to the wider research community for analyses.
Discussion: Analysis of pooled IPD has the potential to inform and direct future practice, research and policy at
low cost, enhancing the value of existing data and reducing research waste. We aim to create a permanent archive
for care home trial data and welcome the contribution of emerging trial datasets.
Keywords: Care homes, Long-term care, Individual participant data (IPD), Randomised trials, Minimum dataset, Data
sharing
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Introduction
Background and rationale {6a}
Approximately 418,000 people live in care homes in the
UK, yet accessible, reliable data on care homes, their
residents and staff are lacking. The dearth of accessible,
high-quality data has been highlighted previously, but
was starkly exposed in the recent and continuing
COVID-19 pandemic [2]. Information about care home
capacity, staffing, health and social care needs and resi-
dent demographics are each required in order to inform
resource allocation and meet their care needs. Adminis-
trative data (e.g. UK Office of National Statistics census)
provides information about age, sex and demographic
change in care home population over time, but cannot
be readily linked to the long-term health, function or
quality of life of individual residents. Length of stay, life
expectancy and mortality of the care home population
are not reliably known. Large cohort studies of older
adults give much richer health data, but the proportion
of care home residents in such studies is low [3, 4]. For
example, Cognitive Function and Ageing Studies (CFAS)
reports on 543 residents and English Longitudinal Study
of Ageing (ELSA) reports on 303 residents [5, 6]. Inter-
nationally, large care home datasets are available, for ex-
ample, through insurance schemes in private healthcare
systems. However, with any routinely collected data,
there are concerns over data quality, and for many of
these registers, the data collected speak to a certain pur-
pose only and may not contain the most relevant clinical
information. In addition to problems sourcing data
about residents, it is also difficult to find consistent in-
formation about the fragmented care home market, in-
cluding staffing (ratios and retention), case mix, funding
mix and ownership. The lack of publicly available na-
tional data on the care home sector is detrimental to
those who live and work there. By failing to quantify the
needs of those requiring care and their journey before
entering care homes, local and national planning for the
care needs of the ageing population living with demen-
tia, multimorbidity and frailty is impaired [7]. For ex-
ample, it is estimated that care home capacity will need
to expand to facilitate care for those with complex needs
to receive care at the end of their lives [8, 9]. However,
current staffing, funding source, resident pathways to
care and capacity to provide care are unknown.
Large randomised controlled trials (RCTs) conducted
solely in care homes are a growing resource [10],
collecting detailed information about every care home
and resident they recruit. Whilst these RCTs may focus
on a variety of health/care topics (e.g. falls risk,
medication management, nutrition or infection) from
the study team’s experience of working with various care
home trials, we know that there is much overlap in
outcome measurement and information collected on
both residents and the care home structure. Trials in
care homes monitor participants regularly, often for up
to 1 year. Outcome measures, health resource use and
clinical events as well as care home characteristics can
therefore be tracked over this period, allowing for
longitudinal analysis. Secondary analysis of individual
participant data (IPD) allows for more complex and
flexible analyses than is possible with only summary-
level results. Whilst single care home trial datasets are
valuable, if IPD from existing trials could be pooled, they
would collectively provide a much larger, richer dataset
on residents and staff of care homes. Repurposing care
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home trial data would permit rapid synthesis of large
IPD through which to generate evidence based on high-
quality data. This principle aligns with current moves to-
wards improving efficiency and reducing research waste
[11], a theme of increasing importance to funders and
peer reviewers. Pooled IPD would permit exploratory
analysis to better understand the care home population,
reduce duplication of effort and refine and pilot future
research questions. The International Committee of
Medical Journal Editors has reiterated its commitment
to improve trial transparency by sharing IPD from RCTs
and registries [12] and strive to normalise the sharing of
de-identified trial data [13]. Clinical trials units have also
signalled their support [14], and all trials started after
January 1, 2019, must include an IPD sharing plan in
their trial registration [13].
Data repository models
Clinical data repositories such as Clinical Study Data
Request (CSDR), Project Data Sphere and Yale
University Open Data Access (YODA) Project are
available to access IPD from single trials [15]. To allow
data from multiple trials to be pooled into a single
source within a secure data infrastructure, we will
replicate the model developed by the Virtual Trials
Archives (VTA) [16]. VTA was established in 2001,
bringing together multiple, large, international data sets
from completed clinical trials on stroke research [17,
18]. It has since expanded to include two additional
repositories in areas of cardiovascular and cognition
(VICCTA) and renal transplantation (VIRTTA) [19].
VTA is a not-for-profit collaboration, with datasets
hosted by the Robertson Centre for Biostatistics (RCB)
at the University of Glasgow, UK. The VTA facilitates a
wide range of empirical and methodological research in-
cluding recent projects on test accuracy [20], psycho-
metrics [21], prognosis [22] and trial design [23]. Unlike
with a traditional IPD meta-analysis [24, 25], a key tenet
is that data should be used for novel research and not to
test original hypotheses from contributed RCTs, though
IPD meta-analyses are possible with permission of con-
tributing trialists. Investigators can access data by
submitting a research proposal on the VTA website. Fol-
lowing approval by the relevant repository Steering
Committee (a virtual collaboration of the original trial-
ists), data extraction is tailored to the specific research
question, and the requesting investigator is granted ac-
cess to analyse the bespoke data extract on a secure, on-
line analysis platform, adhering to data security standard
operating procedures. On completion, the anonymised
data extract is archived centrally. The VTA is funded by
administrative charges per data request, which supports
data curation, storage, continued development and day-
to-day administration of the resource. VTA has a well-
established governance infrastructure, with the ability to
host data securely on a working data-sharing platform,
and expertise to manage future trial inclusion and
data access requests. To enable the care home trial
repository to operate on a long-term basis, we are
working closely with the VTA from the outset. Once
operational, the repository will formally migrate to
the VTA, where it will be named the Virtual Inter-
national Care Homes Trials Archive (VICHTA; see
Fig. 1 and Table 2 in Appendix 3).
This protocol describes the creation of a care home
trial repository as part of a funded project (the
Developing research resources And minimum data set
for Care Homes’ Adoption and use (DACHA) study;
hereby described as the ‘development stage’) and also
outlines plans for operation of the VICHTA repository
that will be accessible beyond the DACHA study (hereby
described as the ‘operational stage’). Our aims are to
create a repository of IPD from RCTs conducted in
adult care homes and use the repository data to conduct
analyses to inform a care home minimum dataset
relevant to the UK context [26].
Study objectives {7}
Development stage (DACHA study)
1. Create a repository of IPD from trials conducted in
UK care homes since 2010
2. Set up a Trialist Steering Committee, who will
oversee data sharing and remain gatekeepers of
their own trial data
3. Compare the pooled IPD with point estimates from
administrative sources to assess generalisability of
RCT data
4. Identify key resident characteristics and outcomes
from within the trial repository, which could inform
a national minimum dataset for care homes
Operational stage (Virtual International Care Home Trials
Archive (VICHTA))
1. Enable new trials to be added to the repository
beyond the DACHA project duration, including
those from non-UK settings
2. Make pooled IPD available to external researchers
to allow future secondary analysis
Study design {8}
There will be four phases:
 Phase 1: Identifying trials and establishing the
Trialist Steering Committee (TSC)
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 Phase 2: Creating the repository, preparing data and
pooling individual trial datasets
 Phase 3: Analysis of pooled data to inform DACHA
study objectives
 Phase 4: Preparing for migration to Virtual Trials
Archive and operation as VICHTA
Phase 1: Identifying trials and establishing the Trialist
Steering Committee
To be included in the proposed repository, trials must
meet the following eligibility criteria {10}:
 Examination of any intervention conducted
exclusively in an adult care home setting
 Minimum dataset of 100 participants
 Completed since 2010
 Trial conducted in the UK {9}
 Documented entry criteria
 Documented participant consent or assent following
Health Research Authority approved procedure
 Monitoring procedures exist to validate data
Internationally, there is significant heterogeneity in the
terminology used in practice and research to describe
the settings in which long-term care is delivered [27,
28]. We have used the term ‘care home’ to describe care
facilities that provide 24-h care to their residents, includ-
ing those with and without on-site registered nursing
staff.
Identifying trials
A scoping review identified potential care home trials
for inclusion. As part of preparatory work, we contacted
a small number of trialists who had completed RCTs in
UK care homes to date. Based on provisional agreement
from five of these trialists, we anticipate the repository
will initially combine trial data for over 4200 residents
Fig. 1 Data processing flowchart
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from 250 care homes across the UK. Through an
ongoing scoping review, we have identified a further
thirteen potential trials, representing an additional 6000
residents from approximately 500 care homes. We
anticipate this will increase further as the project
develops, including the recruitment of international
studies in the legacy dataset. Additional trials will be
identified through an ongoing Google Scholar alert,
systematically through concurrent reviews (Prospero:
CRD42020155923), by contacting all trialists listed in the
NIHR ‘Advancing Care’ Themed Review [10] (44 studies
featured), the CLAHRC National Work stream Report
[29] (32 studies featured), and snowballing techniques
utilising the DACHA project management team, study
steering committees and their professional networks.
Approaching/inviting trialists to share their data
We have created a database to track potentially eligible
trials, where we will record how IPD are requested,
collected and managed, and log of all contact with
trialists. We will write to original trialists explaining the
purpose of the repository and how it will operate. A
reminder email will be sent 2 weeks after the initial
contact if the trialist has not responded. If the trialist
declines or does not respond, we will log this dataset as
unavailable. Following a positive response, we will set up
a meeting (phone, Zoom or face to face depending on
trialist preference) to outline the project in more detail.
If a trialist agrees to participate, they will be asked to
sign a data transfer agreement that covers the transfer,
use and storage of their trial data (see Terms of
Reference, Appendix 1).
Establishing Trialist Steering Committee (TSC)
Contributing trialists will make up the TSC to oversee
sharing, combining and repurposing of the pooled trial
data. Whilst day-to-day co-ordination will be led by the
DACHA co-ordinator at University of Hertfordshire (LI)
and latterly the Virtual Trials Archive (MA), the TSC
will agree on Terms of Reference for the collaboration,
including the approval process for data requests, and will
have the ultimate responsibility for all decisions regard-
ing strategy, confidentiality, scientific matters and
determining publication policy. This system mirrors the
VTA, to which the care home repository will ultimately
migrate.
The main role of the TSC during the DACHA-funded
phase will be to provide advice on trial-specific details to
aid with the pooling of datasets and better understand-
ing of original data. Key information will be drawn from
the original trial protocol, funders report and standard
study documentation such as case report form templates
and statistical analysis plans, but if any issues are not
dealt with from those sources, we will seek clarification
from the original trial team.
Phase 2: Creating repository, preparing data and pooling
individual trial datasets
Contributing trial data to repository
Once an agreement has been made to contribute data,
trial data managers (e.g. within clinical trials units
(CTU)) will be engaged to prepare datasets. As standard
practice with individual participant data sharing models
[30], only completely anonymised data will be held in the
repository, to minimise the risk of reidentification. We
will request that all data received will be fully de-
personalised (such as converting ‘date of birth’ to ‘age at
randomisation’). Full instructions on de-identification
and how to transfer securely will be provided if
necessary.
Additional documents to support datasets will be
requested, including the trial protocol and data
dictionary. Optional supporting documents will include
blank, annotated case report forms, statistical analysis
plans, relevant published outputs or grey literature about
the trial. We will request evidence of ethical approval
and consent procedure (e.g. blank consent and/or assent
forms).
Repository data storage
The Virtual Trials Archive team have developed a
DACHA data contribution form [16] where trialists can
record information about the trial and complete a data
sharing agreement. Following this, the trial dataset and
all accompanying files will be transferred in a zipped,
password-protected folder to the University of Glasgow’s
RCB, using the University of Glasgow’s File Transfer
Protocol, where it will be held securely for the duration
of the DACHA study and beyond. As it does for other
VTA repositories, the RCB will act as an independent
data host, providing common format and access mecha-
nisms. All data will remain on their server and analysed
through their secure analysis platform, in accordance
with standard conventions for data sharing initiatives.
During the development stage, access to the data will be
restricted to the core team (LI, JB and MA), who have
undergone necessary data protection and confidentiality
training. At the end of the DACHA project, the VTA
will act as custodians of the data under the terms of the
data transfer agreement.
Data preparation and quality checks
When trial data are submitted to the repository, the
DACHA co-ordinator (LI) at the University of Hertford-
shire (UH) will access the server remotely via a secure
virtual private network. A data checking analysis plan
will be developed, outlining procedures and decision
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rules for data pooling, according to established princi-
ples [30]. We will query any anomalies, including checks
for invalid, out-of-range or inconsistent items with the
trialist (or their nominated study contact) to ensure that
the data are represented accurately. Trials may use the
same outcome measure but administer it differently. If a
measure could be completed, e.g. face-to-face with a
member of the research team, or as self-report or as
proxy-response from care staff, we will ensure this data
are coded in a standardised way. Decisions on the stand-
ardisation will be made by consensus decisions with the
wider TSC or delegated groups, e.g. trial statisticians.
Where possible, we will request all individual domain
scores for outcome measures as opposed to the single,
composite scores. All trial datasets will be cross-checked
against their respective protocol and statistical analysis
plan to confirm how each composite outcome was de-
rived. If the scoring was modified, we will seek clarifica-
tion from the respective trialists in the TSC for their
advice and interpretation on whether the composite out-
come data should be removed or amended to enable
pooling with other trial datasets. We will record the
number and timing of measurement points and ensure
all time points are labelled consistently.
We anticipate there will be a strong opportunity for
methodological research to look at groups of measures,
e.g. cognitive assessments, to attempt mapping or
potentially harmonising similar variables [31, 32]. We
would encourage external researchers to look at this in
the operational phase; however, in the development
phase, we will not attempt to harmonise non-matched
data.
We anticipate most RCTs with an economic
evaluation component will use a variant of the Client
Service Receipt Inventory (CSRI) [33] to record
information on resource use and costs alongside the
trial. We will request all health service use
questionnaires used in the trials and look for
differences which may potentially impact the findings.
Due to differences in price years and interpretation of
unit costs, we will focus on resource use (e.g. number
of GP contacts) as opposed to costs (e.g. total cost of
GP contacts over the follow-up period). We will re-
quest datasets to include missing values where pos-
sible and not the imputed values. In developing the
repository, we will not perform any missing data
imputation.
Database of trial summaries
We have collated aggregate data available in each trial
(generated through protocol papers and funders reports)
and will build on this database as new trials are
published. A summary of available data will be published
on the VTA website, allowing viewers to identify what
outcome measures have been collected multiple times,
how care home characteristics have been recorded and
contextual aspects of each trial, e.g. sample size and
follow-up points.
The repository will host trials with a range of
clinical focus—it is therefore likely that some
measures will be unique to single trials. However, a
combination of several key outcome measures—e.g.
Barthel, Mini-Mental State Examination (MMSE),
European Quality of Life Scale (EQ 5D) and Quality
of Life assessment in Dementia (DEMQoL) [34–37],
is used in almost all RCTs conducted in care homes.
Additionally, clinical indicators such as hospitalisa-
tions, falls and death rates are routinely reported (see
Table 1 in Appendix 2: examples of data available
from each trial.)
Phase 3: Analysis of pooled data to inform DACHA study
objectives
When the initial set of trials has been added and
variables prepared for pooling, we will temporarily lock
the repository to allow two pre-specified analyses:
1. Identification of key resident characteristics and
outcomes from within the trial repository, which
could be used to inform the development of a
minimum dataset (MDS) for care homes
2. Comparison of the pooled individual participant
data with point estimates from administrative
sources to assess the generalisability of RCT data
We will prepare a detailed research plan for each
analysis, outlining the purpose of the request, objective/
research question, plan for statistical analysis and
repository variables requested. This research plan will
then be circulated to the TSC for approval, as per future
data requests from external analysts.
Informing development of a prototype minimum dataset
(MDS) for care homes
Briefly, we will expand focus on what clinical,
demographic and outcomes data from trials may be
appropriate to include in a care homes MDS
framework. We will categorise outcome measures into
broad areas, e.g. cognition, anxiety and depression,
pain, mobility, activities of daily living (ADLs) and
specific clinical measures, and will focus on pre-
specified outcome measures, in part identified through
existing work on evidence reviews (PROSPERO
CRD42020155923 and CRD42020171323). This identi-
fication and critique of relevant outcome measures
within existing trials will help inform the development
of a prototype MDS [26]. We will develop a quality
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assessment criterion to assess proposed outcome mea-
sures in terms of the following:
 What has been measured—baseline, processes of
care, outcomes
 How data were collected (resident notes, researcher
observation/assessment, use of routine data sources)
 Completeness of the data and where data are
incomplete, what is the nature of this (i.e. death,
unavailable, withdrawn consent, unable to complete,
unclear)
 Where outcomes are measured across multiple
studies, what are the range of values
 Where outcomes are measured over time, what is
their sensitivity to detect change
 What information may be derived from collected
data, e.g. comorbidity scoring based on medication
usage
Generalisability of trial data
Briefly, we will conduct an evidence synthesis of key
care home demographic information, by collating
data from administrative sources, e.g. UK Census,
Care Quality Commission. We will report baseline
characteristics about care homes and residents as
derived from all pooled trial data, tabulated for each
individual trial and the pooled dataset. We will then
compare point estimates from administrative sources
with point estimates from the pooled IPD trial data,
to evaluate how generalisable the repository data are,
compared to alternative data sources.
Phase 4: Preparing migration to Virtual Trials Archive
The VICHTA repository will be a legacy output of
the DACHA project—a valuable source of high-
quality, anonymised IPD to inform the development
of future research, testing of hypotheses and optimisa-
tion of study design issues. We took an early decision
to store all trial data solely on the University of Glas-
gow secure server, where the VTA is also housed.
This means the repository will already have a per-
manent ‘home’ when the DACHA study ends. Man-
agement of the repository will be transferred from the
DACHA team at the University of Hertfordshire (LI,
CG) to the VTA team at the University of Glasgow
(principally the VTA co-ordinator, MA). The VTA
will maintain and update the VICHTA repository, and
manage requests to access its data, in conjunction
with the existing TSC.
Following formal migration to the VTA, external
researchers may apply for data extracts, by submitting
a project proposal (for review and approval by the
TSC) and agreeing to the predefined VTA data
sharing terms and conditions (see Appendix 1). At
the proposal stage, TSC members may declare an
interest in joining the analysis team of a proposed
project and take an active role, thereby meeting the
ICMJE criteria for authorship. All completed analyses
will be forwarded to the TSC before submission for
presentation or publication for review (see the data
processing flowchart). The TSC is acknowledged on
all publications using ‘on behalf of VICHTA
collaborators’ by-line. Active involvement from each
TSC member is encouraged but not essential, as data
request decisions will be made by a quorum (see
Table 2 in Appendix 3: summary of development and
operational phases).
Oversight and monitoring
Data protection considerations {27}
In sharing any form of IPD, protection of personal
privacy must be upheld [38]. A key factor to achieve this
is to ensure trial data must be fully anonymised before it
is added to the repository, to minimise the risk of
reidentification. Electronic data will be stored securely
on University of Glasgow server and will not be
transferred or copied to any other location. Any paper
documentation linked to the study will be scanned and
stored as electronic data in the DACHA Study OneDrive
as well as within the RCB servers. The paper version will
then be destroyed. Together with the Data Protection
Officer at the University of Hertfordshire, we have
completed a Data Protection Impact Assessment to
cover the research period of the DACHA study.
Research governance {5d}
The University of Hertfordshire is the sponsor for the
study, and their Ethics Review Board has approved this
methodology (HSK/SF/UH/04185 approved 18 June
2020). Virtual Trials Archive has overarching university
ethical approval for all their repositories and will update
this through the University of Glasgow to include VICH
TA. VTA will ask for indefinite ethics approval, subject
to regular but infrequent reports at the discretion of the
REC, e.g. 5-yearly, to minimise the administrative bur-
den on both sides.
Data security
Access to data extracts is restricted to individuals
who have been granted access by the TSC only. The
RCB is certified for ISO 9001:20015 for its Quality
Management System and to ISO/IEC 27001:2013 for
its Information Security Management System. RCB is
audited every 6 months by the British Standards in
Industry (BSI) and is regularly audited by its sponsors
and clients both prior to and during studies. RCB has
extensive experience in managing data in the context
Irvine et al. Trials          (2021) 22:157 Page 7 of 11
of privacy and data protection legislation, including
the Data Protection Act 2018 and EU General Data
Protection Regulation. Extensive data security
procedures are in place including firewall protection,
virus detection, daily backups, routine transaction
logging, restricted access and on-site and off-site fire-
proof storage of backups.
DACHA project management
The Virtual Trials Archives are coordinated on behalf of
the steering committees by MA (a coordinator with
more than 10 years of experience in running VTA).
During the DACHA study, the TSC will be co-chaired
by JB (co-investigator on DACHA) and TQ, also based
at the University of Glasgow and experienced in chairing
other VTA repositories. Chairmanship can be reassigned
at the nomination of the TSC. The research team has
extensive clinical trials experience and all members are
familiar with handling confidential anonymised personal
health data.
The DACHA project has an independent Steering
Group which will oversee this work package and the
wider aims of developing a minimum dataset for care
homes. This committee meets twice per calendar year.
PPIE and public consultation {31a}
Patient and public involvement and engagement
(PPIE) for the DACHA study will be led by the
University of East Anglia and our expert-by-
experience co-applicant (a family carer). PPIE will be
represented on the DACHA independent steering
group by two carers with family living in care homes.
A PPIE panel is planned to work as the hub of PPIE
activities, made up of 8–10 people representing care
home staff, managers, family carers of care home resi-
dents and representatives of people with dementia.
This group will meet 4-monthly, initially virtually.
The care home resident PPIE contribution will be
supported through two groups based in Norfolk care
homes.
In addition to the PPIE panel, DACHA will have four
regional groups of Expert Consultation groups, meeting
annually. During these meetings, we will explain what
data will be available in the trial repository, and then ask
members to identify research topics that may be
important for further investigation. Residents, their
relatives, care home workers and managers are better
placed to prioritise research questions on a more
practical level; therefore, this exercise will ensure the
right issues are being addressed.
Discussion
This protocol defines the methods to curate a repository
of care home trials for IPD analysis. It uses the existing,
established infrastructure of the Virtual Trials Archive
[1] to create this resource for informing the DACHA
study and generating a legacy repository which will be
expanded to include international care home trial
datasets for future researchers. This represents an
efficient use of existing research resources, enhancing
the value from existing data and reducing waste [39, 40].
We are aware of one IPD meta-analysis combining the
US and Dutch nursing home data [41], but this is the
first attempt to develop a care homes repository, to
which new trials can continually be added. This model
can and has been replicated across a range of health
conditions, including stroke, atrial fibrillation, ischaemic
heart disease, heart failure, diabetes and metabolic con-
ditions, cognition, renal transplantation (http://www.
virtualtrialsarchives.org/) and aphasia (https://www.
aphasiatrials.org/aphasia-dataset/).
Those living in care homes are a vulnerable
population, and research in this setting is challenging,
not least due to high rates of incapacity and dementia
[42]. Re-use of data is efficient, minimising burden
and intrusion to residents and staff and reducing the
need for primary data collection. It adds value to the
original trial question—whilst most trials are framed
as health research questions, IPD provides the oppor-
tunity to address the questions and priorities of social
care, including experiences of living and dying in care
homes. In the absence of standardised data sets about
care home residents, trial data will help us to under-
stand more about this under-researched population.
Curating a resource which is based on the setting of
care, rather than being disease-specific, is attractive as
we recognise that many of the challenges posed by
health and care services are in caring for those with
complex multimorbidity. Furthermore, there are les-
sons to improve future trial design, by exploring the
value of the assessments and measures used in care
home trials, to understand their utility, feasibility and
relevance to care home life. Many of these tools were
designed for use in community-dwelling adults or
those in hospital settings and their applicability to the
population living in care homes has yet to be estab-
lished. IPD analysis can help address these questions,
which are otherwise unanswered.
Study status
Protocol version 4.
The project began on January 6, 2020. It is funded
via the DACHA Study (NIHR127234) until October
30, 2023, after which the repository (VICHTA) will
be maintained by the Virtual Trials Archive. We
anticipate pooled datasets will be available for sharing
by late 2023.
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Appendix 1: Trialist Steering Committee: Terms of
Reference
The Virtual International Care Home Trials Archives (VICH
TA) terms and conditions for Steering Committee
Membership
The Virtual International Care Home Trials Archives
(VICHTA) will be an international repository for
anonymised data from completed clinical trials that were
set in care homes. This will be a not-for-profit collabor-
ation hosted by the Robertson Centre for Biostatistics
and the University of Glasgow.
Data will primarily be sought for use in the
‘Developing research resources and minimum data set
for Care Homes’ Adoption and use’ (DACHA) study and
will be contributed to VICHTA upon completion of the
project to form a legacy dataset that can be interrogated
for novel exploratory analyses. As per existing
regulations that govern the stroke and cardiovascular
sister archives (VISTA and VICCTA, respectively), we
will not permit the reanalysis of treatment effects or
reanalysis of the aims of the original trials.
Trialists that contribute anonymised RCT data to
VICHTA will form the Steering Committee (1
named representative per trial, as per existing
regulations). The role of the Steering Committee will
be to:
1. Provide any additional information about relevant
trial’s data, as appropriate, to aid in data cleaning
and compilation
2. Review proposals to use data from VICHTA for
novel exploratory analyses
3. Provide constructive feedback and peer review of
proposals and papers
The Steering Committee members may also declare an
interest in joining the analysis team of a proposed
project provided that they take active participation in
the project and meet the criteria for authorship stated by
relevant journals. All declarations of interest should be
made at the proposal circulation stage, and not at the
paper review stage.
All papers that are generated as a result of VICHTA
analyses will carry the by-line ‘on behalf of the VICHTA
Collaborators’, and a full list of the Steering Committee
members will be included in the appendix of all
manuscripts.
Whilst we understand that reviewing proposals,
abstracts and manuscripts can take some time, we
appreciate active involvement from each Steering
Committee member. If, however, certain members are
unable to actively review all outputs, decisions will be
made by a quorum.
Appendix 2
Table 1 Examples of data available from each trial
Type of data Examples of data available
Trial level Study design
Duration of follow-up
Timing of assessment points
Intervention details
Region/geographical area covered
Care home level Staff ratios; staff retention
Number of beds; bed occupancy rates
Case mix; funding mix; ownership





Medical conditions, e.g. Y/N presence of dementia, diabetes, COPD, previous stroke
Time living in care home
Status at end of follow-up (alive/dead/lost to follow-up)
Cause of death




Outcome measures Individual domain levels
Summary scores
Resident-reported, carer-reported or researcher-reported responses
Baseline measures
Follow-up measures
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Appendix 3
Table 2 Development and operational phase differences
DACHA (funded up to November 2023) Virtual Trials Archive (December 2023 onward)
Name DACHA Trials repository Virtual International Care Homes Trials Archive (VICHTA)
Funding HS&DR NIHR127234 Supported through data access fees
Analysis • Internal to WP2 team only
• Analysis on University of Glasgow (UG) server (VPN access
for LI)
• Focus on descriptive statistics
• Available to external researchers via for data request
process
• All analysis performed on VTA Analysis Platform
• More advanced statistical analysis
Management University of Hertfordshire (UH) and Virtual Trials Archive/
Robertson Biostatistics Centre (UG)
Virtual Trials Archive/Robertson Biostatistics Centre (UG)
Inclusion criteria • UK only
• RCTs only
• Older adult focus
• At least 100 participants
• Any intervention/condition
• Published since 2010
• Evidence of resident/consultee consent
• Add non-UK studies
Publication policy All TSC members full authors for the main paper describing
the development of repository.
For other publications arising:
• By-line ‘on behalf of VICHTA collaborators’
• Option to get involved in research and full authorship
dependent on ICMJE guidelines.
By-line ‘on behalf of VICHTA collaborators’
Option to get involved in research and full authorship
dependent on ICMJE guidelines.
Analyses • Generalisability of RCT data
• Using the repository to inform Minimum Dataset
Open for external researchers
Independent Oversight DACHA Steering Group Robertson Biostatistics Centre, UG
PPIE Led by Anne Killett and Priti Biswas at UEA
Ethics University of Hertfordshire HSK/SF/UH/04185 approved 18
June 2020
Amendment for VTA ethics via UG
Trialist Steering Committee
(TSC) membership
Co-chairs: Jenni Burton and Terry Quinn
Up to two representatives per trial—principle investigator;
CTU delegate; statistician; ECR
Minimal face-to-face contact; Zoom conferencing
Chair/co-chair may rotate over years
Minimal face-to-face contact
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